VXRTWhite card, red-hot board fight
Vaxart is asking shareholders to vote FOR all six of its board nominees on the WHITE proxy card today, a clear sign this annual meeting is turning into a full-on proxy contest. The company says its nominees are the only ones who can keep its value-creation plan moving, and it’s taking a swipe at the dissident slate by arguing those candidates lack relevant biotech and public-company leadership experience.
Why you should care
If you own VXRT, this isn’t just corporate theater in a conference room with bad coffee. Proxy fights can change who controls strategy, capital allocation, and even whether a company keeps following the same playbook or suddenly pivots hard.
For a clinical-stage biotech like Vaxart, board control matters because the whole story is basically:
- can management keep funding the science?
- can it convince investors the pipeline is worth the patience?
- and who gets to steer the ship if the current plan keeps running into headwinds?
The clock is ticking
The company says its annual meeting is scheduled for July 16, 2026, so this campaign is still in the persuasion phase. But once the votes get counted, shareholders will find out whether the current board keeps the keys or whether activists get a shot at rerouting the car.
Big picture: when a biotech starts talking this much about board nominees, it’s usually because the science story and the shareholder patience story are no longer perfectly aligned.